Cambridge's Akebia Therapeutics, Inc. Hauls In $100 Million In Upsized IPO Debut

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Akebia Therapeutics, a biotech developing a breakthrough anemia treatment with a once-daily oral dose, raised $100 million in an upsized IPO by offering 5.9 million shares at $17, the high end of the range of $14 to $17. The company had originally planned to offer 4.9 million shares. Akebia Therapeutics plans to list on the NASDAQ under the symbol AKBA. Akebia Therapeutics initially filed confidentially on 12/20/2013. Morgan Stanley, Credit Suisse and UBS Investment Bank acted as lead managers on the deal.

Help employers find you! Check out all the jobs and post your resume.

Back to news